Mota-T Ciwon ƙwayar cuta, CAR T Therapy, T-Cell CAR, wakili na chimeric
Zurfafa Zurfi cikin CAR T Cell Therapy: Yaya Aiki yake?
Gano kimiyyar da ke bayan CAR T Cell therapy magani a Indiya! Bincika yadda wannan maganin juyin juya hali ke canza ƙwayoyin garkuwar jikin ku zuwa mayaƙan ciwon daji. Karanta blog ɗinmu yanzu don ƙarin koyo game da wannan maganin ban mamaki da yadda ..
Mota-T Ciwon ƙwayar cuta, T-Cell CAR, Mai karɓar Agent Chimeric, Korea, Seoul, Koriya ta Kudu
Kamfanoni a Koriya sun ɗauki mataki kusa da haɓaka haɓakar CAR T-Cell na gida
Mayu 2023: Chimeric antigen receptor (CAR) T-cell far wani sabon ci gaba ne a fagen maganin kansar mutum. Nasu T-cells na majiyyaci ana gyaggyarawa ta kwayoyin halitta yayin aikin kera don bayyana wani.
fasahar binciken halittu, Mota-T Ciwon ƙwayar cuta, T-Cell CAR, CAR far, Sin, tara kudi, Oricell Therapeutics
Oricell yana haɓaka ƙarin $45M USD don faɗaɗa maganin CAR T-Cell zuwa Amurka
23 ga Maris, 2023: Na'urar rigakafin ciwon daji da farkon matakin da Shanghai Biotech Oricell ke samarwa sun sami ƙarin dala miliyan 45 a cikin tallafi, kamfanin ya sanar a ranar Talata. Bayan an nuna shi a AS..
Australia, Mota-T Ciwon ƙwayar cuta, CAR T Therapy, Cartherics
Peter MacCallum Cibiyar Ciwon daji da Cartherics za su yi aiki tare kan ciwon daji na ovarian CAR-T cell far.
Maris 2023: Peter MacCallum Cancer Center (Peter Mac) a Ostiraliya da Cartherics Pty Ltd sun shiga yarjejeniyar ci gaba na haɗin gwiwa (CDPA) don haɓaka CTH-002 don maganin ciwon daji na ovarian. Ku cli..
Mota-T Ciwon ƙwayar cuta, T-Cell CAR, Emily Littlejohn, immunology, lupus farfadowa
Sabuwar maganin CAR T-Cell a cikin farfadowa na Lupus
Feb 2024: Sabbin magunguna da yawa da kuma hanyoyin kwantar da hankali, irin su chimeric antigen receptor T-cell therapy, sun haifar da “farfadowa” don lupus, a cewar mai magana a wurin taron Basic and Clinical Immunology for the Busy ..
anti-BCMA, Mota-T Ciwon ƙwayar cuta, Saukewa: CT103A, FDA, IASO Biotherapeutics, Innovent Biologics, nadin magungunan marayu
CT103A, CAR T-cell Therapy, FDA ta ayyana shi azaman maganin marayu.
Feb 2023: The FDA has granted orphan drug status to CT103A, an experimental CAR T-cell therapy being developed by IASO Biotherapeutics and Innovent Biologics to treat relapsed or refractory multiple myeloma. Orphan drug design..
Mota-T Ciwon ƙwayar cuta, Sin, IASO Biotherapeutics, Multi myeloma
CAR T-cell magani daga IASO Biotherapeutics yana karɓar sabon amincewar FDA
Feb 2023: IASO Biotherapeutics' binciken CAR T-cell far don sake dawowa ko refractory multiple myeloma (RRMM), CT103A, ya sami saurin sauri da kuma sabunta magunguna na ci-gaba na nadi daga Abinci na Amurka da ..
Mota-T Ciwon ƙwayar cuta, Seoul, Koriya ta Kudu
AMC ta buɗe cibiyar CAR T-Cell a Seoul
Jan 2023: Cibiyar Kiwon Lafiya ta Asan (AMC) ta bude cibiyar kula da kwayar cutar ta CAR-T ta farko a cikin kasar bayan gwamnati ta amince da fa'idodin inshorar lafiya ga Kymriah's CAR-T cell therapy.AMC ta sanar a ranar Talata cewa ta iya…
Gwajin Jini, Mota-T Ciwon ƙwayar cuta, JAMA Oncology, sarkar haske neurofilament, Matsalolin Neurotoxic, Jami'ar Washington
CAR T-Cell za a iya annabta rikitarwa ta hanyar gwajin jini mai sauƙi
Satumba 2022: Maganin ciwace-ciwace daban-daban an canza su ta hanyar rigakafi ta tushen tantanin halitta, wanda aka fi sani da CAR-T cell far. Don yin niyya da magance takamaiman nau'ikan cutar sankarar bargo da lymphoma, maganin yana amfani da kwayoyin halitta.
Mota-T Ciwon ƙwayar cuta, Abubuwan da aka bayar na CARsgen Therapeutics Co., Ltd, Kamfanin Daiichi Sankyo, Farashin DLBCL, Binciken Gaggawa, Limited, Novartis AG
Kasuwar jiyya ta CAR T-Cell za ta yi girma cikin ƙimar ban mamaki a cikin shekaru 8 masu zuwa
Yuli 2022: Dangane da binciken da aka yi kwanan nan wanda Binciken Emergen ya gudanar, kasuwar duniya don maganin CAR T-cells ya kai girman dala biliyan 1.29 a cikin 2021 kuma ana sa ran yin rijistar kudaden shiga CAGR na kashi 24.9.